{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:25:30Z","timestamp":1714436730279},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00108-024-01703-5","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T14:03:34Z","timestamp":1712757814000},"page":"439-446","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Katheterbasierte und operative Therapie bei Mitralklappenvitien","Catheter-based and surgical treatment of mitral valve diseases"],"prefix":"10.1007","volume":"65","author":[{"given":"Mirjam G.","family":"Wild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Bothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Czerny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Besler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"issue":"14","key":"1703_CR1","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1161\/CIRCULATIONAHA.119.041080","volume":"140","author":"B Iung","year":"2019","unstructured":"Iung\u00a0B et\u00a0al (2019) Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey. Circulation 140(14):1156\u20131169","journal-title":"Circulation"},{"issue":"18","key":"1703_CR2","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/eurheartj\/ehu449","volume":"36","author":"L Zuhlke","year":"2015","unstructured":"Zuhlke\u00a0L et\u00a0al (2015) Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart\u00a0J 36(18):1115\u2013122a","journal-title":"Eur Heart J"},{"issue":"7","key":"1703_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian\u00a0A et\u00a0al (2022) 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart\u00a0J 43(7):561\u2013632","journal-title":"Eur Heart J"},{"key":"1703_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab395","author":"A Vahanian","year":"2021","unstructured":"Vahanian\u00a0A et\u00a0al (2021) 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab395","journal-title":"Eur Heart J"},{"key":"1703_CR5","doi-asserted-by":"crossref","unstructured":"Wilkins GT et al (1988) Br Heart J 60:299\u2013308","DOI":"10.1136\/hrt.60.4.299"},{"key":"1703_CR6","doi-asserted-by":"crossref","unstructured":"Iung B et al (1996) Circulation 94:2124\u20132130","DOI":"10.1161\/01.CIR.94.9.2124"},{"issue":"25","key":"1703_CR7","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/eurheartj\/eht097","volume":"34","author":"C Bouleti","year":"2013","unstructured":"Bouleti\u00a0C et\u00a0al (2013) Reinterventions after percutaneous mitral commissurotomy during long-term follow-up, up to 20\u00a0years: the role of repeat percutaneous mitral commissurotomy. Eur Heart\u00a0J 34(25):1923\u20131930","journal-title":"Eur Heart J"},{"key":"1703_CR8","doi-asserted-by":"crossref","unstructured":"Silbiger, J.J., Advances in Rheumatic Mitral Stenosis: Echocardiographic, Pathophysiologic, and Hemodynamic Considerations. J\u00a0Am Soc Echocardiogr, 2021. 34(7): p.\u00a0709\u2013722 e1.","DOI":"10.1016\/j.echo.2021.02.015"},{"issue":"18","key":"1703_CR9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.jcin.2023.06.041","volume":"16","author":"ME Guerrero","year":"2023","unstructured":"Guerrero\u00a0ME et\u00a0al (2023) 5\u2011Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes: MITRAL Trial Final Results. JACC Cardiovasc Interv 16(18):2211\u20132227","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"1703_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","volume":"70","author":"RA Nishimura","year":"2017","unstructured":"Nishimura\u00a0RA et\u00a0al (2017) 2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: A\u00a0Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J\u00a0Am Coll Cardiol 70(2):252\u2013289","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1703_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4414\/cvm.2017.00532","volume":"20","author":"M Russo","year":"2017","unstructured":"Russo\u00a0M et\u00a0al (2017) The evolution of surgical valves. Cardiovasc Med 20(12):285\u2013292","journal-title":"Cardiovasc Med"},{"issue":"3","key":"1703_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0022-5223(19)39144-5","volume":"86","author":"A Carpentier","year":"1983","unstructured":"Carpentier\u00a0A (1983) Cardiac valve surgery\u2014the \u201cFrench correction\u201d. J\u00a0Thorac Cardiovasc Surg 86(3):323\u2013337","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"20","key":"1703_CR13","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.jcin.2020.06.019","volume":"13","author":"JG Webb","year":"2020","unstructured":"Webb\u00a0JG et\u00a0al (2020) 1\u2011Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. JACC Cardiovasc Interv 13(20):2344\u20132357","journal-title":"JACC Cardiovasc Interv"},{"key":"1703_CR14","volume-title":"Early procedural outcomes from subjects treated with next-generation MitraClip (NTR\/XTR) system: initial observations from the Global EXPAND study, in EuroPCR","author":"J Hausleiter","year":"2019","unstructured":"Hausleiter\u00a0J (2019) Early procedural outcomes from subjects treated with next-generation MitraClip (NTR\/XTR) system: initial observations from the Global EXPAND study, in EuroPCR. Paris, France"},{"issue":"24","key":"1703_CR15","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone\u00a0GW et\u00a0al (2018) Transcatheter mitral-valve repair in patients with heart failure. N\u00a0Engl J Med 379(24):2307\u20132318","journal-title":"N Engl J Med"},{"issue":"24","key":"1703_CR16","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.jcin.2022.09.005","volume":"15","author":"DS Lim","year":"2022","unstructured":"Lim\u00a0DS et\u00a0al (2022) Randomized Comparison of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients. JACC Cardiovasc Interv 15(24):2523\u20132536","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"1703_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jacc.2016.10.068","volume":"69","author":"DWM Muller","year":"2017","unstructured":"Muller\u00a0DWM et\u00a0al (2017) Transcatheter Mitral Valve Replacement for Patients With Symptomatic Mitral Regurgitation: A\u00a0Global Feasibility Trial. J\u00a0Am Coll Cardiol 69(4):381\u2013391","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"1703_CR18","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner\u00a0H et\u00a0al (2017) 2017 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart\u00a0J 38(36):2739\u20132791","journal-title":"Eur Heart J"},{"key":"1703_CR19","doi-asserted-by":"crossref","unstructured":"Asgar, A.W., M.J.\u00a0Mack, and G.W.\u00a0Stone, Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J\u00a0Am Coll Cardiol, 2015. 65(12): p.\u00a01231\u20131248.","DOI":"10.1016\/j.jacc.2015.02.009"},{"issue":"36","key":"1703_CR20","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA et\u00a0al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"11","key":"1703_CR21","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","volume":"139","author":"DH Kang","year":"2019","unstructured":"Kang\u00a0DH et\u00a0al (2019) Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. Circulation 139(11):1354\u20131365","journal-title":"Circulation"},{"issue":"24","key":"1703_CR22","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","volume":"379","author":"JF Obadia","year":"2018","unstructured":"Obadia\u00a0JF et\u00a0al (2018) Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N\u00a0Engl J Med 379(24):2297\u20132306","journal-title":"N Engl J Med"},{"issue":"8","key":"1703_CR23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jacc.2020.12.047","volume":"77","author":"MJ Mack","year":"2021","unstructured":"Mack\u00a0MJ et\u00a0al (2021) 3\u2011Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. J\u00a0Am Coll Cardiol 77(8):1029\u20131040","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1703_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jcin.2021.03.050","volume":"14","author":"S Higuchi","year":"2021","unstructured":"Higuchi\u00a0S et\u00a0al (2021) Impact of Residual Mitral Regurgitation on Survival After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. JACC Cardiovasc Interv 14(11):1243\u20131253","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"1703_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1161\/CIRCULATIONAHA.120.053061","volume":"144","author":"S Kar","year":"2021","unstructured":"Kar\u00a0S et\u00a0al (2021) Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: COAPT Trial. Circulation 144(6):426\u2013437","journal-title":"Circulation"},{"key":"1703_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2162","volume-title":"Centre procedural volume and adverse in-hospital outcomes in patients undergoing percutaneous transvenous edge-to-edge mitral valve repair using MitraClip(R) in","author":"K Keller","year":"2021","unstructured":"Keller\u00a0K et\u00a0al (2021) Centre procedural volume and adverse in-hospital outcomes in patients undergoing percutaneous transvenous edge-to-edge mitral valve repair using MitraClip(R) in. Eur J Heart Fail, Germany"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01703-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01703-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01703-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T06:03:20Z","timestamp":1714370600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01703-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1703"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01703-5","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"22 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.G.\u00a0Wild hat Vortragshonoraria und Reisekosten\u00fcbernahme von Edwards Lifesciences sowie Vortragshonoraria von Abbott Vascular erhalten. C.\u00a0Besler hat Vortragshonoraria und Reisekosten\u00fcbernahme von Edwards Lifesciences sowie Vortragshonoraria von Abbott Vascular erhalten. D.\u00a0Westermann hat Vortragshonoraria und Reisekosten\u00fcbernahme von Abiomed, Abbott, AstraZeneca, Bayer, B\u00f6hringer Ingelheim, Daiichi Sankyo, Edwards Lifesciences, Medtronic und Novartis erhalten. M.\u00a0Czerny ist Berater f\u00fcr Terumo Aortic und Medtronic, hat Vortragshonoraria von Edwards Lifesciences erhalten und ist Aktienhalter von TEVAR Ltd. und Ascense Medical. W.\u00a0Bothe gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}